Shinichiro Fuse Ph.D Overview
- Firm
- TPG
- Primary Position
-
Partner & Managi...
- Primary Industry
-
Healthcare
- Active Board Seats
-
3
- Med. Deal Size
-
- Med. Valuation
-
Shinichiro Fuse Ph.D General Information
Biography
Dr. Shinichiro Fuse serves as Partner & Managing Director at TPG. He serves as a Board Member at Ouro Medicines. He served as a Board Member at Sanofi Ventures. He served as a Board Member at ReNAgade Therapeutics. He serves as a Board Member at Sudo Biosciences. Previously, he served as Managing Director at MPM Capital. He also served as Senior Manager of Business Development at Bluebird Bio. He served as a Board Member at Orna Therapeutics & Triplet Therapeutics. He served as a Supervisory Board Member of iOmx Therapeutics. He served as an Associate at PureTech Ventures. Before joining PureTech, he was a healthcare consultant with Clarion Healthcare. He completed his doctoral work in Microbiology and Immunology where he published over ten peer-reviewed articles and completed an internship at Morgan Stanley. He serves as a Board Member at Santa Ana Bio. He holds a Ph.D. in Microbiology and Immunology from Dartmouth College.
Contact Information
Address
- 888 7th Avenue
- 35th Floor
- New York, NY 10106
- United States
Shinichiro Fuse Ph.D Positions (1)
| Firm name | Firm type | Title | Location | Industry | Since |
|---|---|---|---|---|---|
| TPG | Investor | Partner & Managing Director | Fort Worth, TX | PE/Buyout |
Shinichiro Fuse Ph.D Board Seats (3)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Ouro Medicines | Biotechnology | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA | |
| Santa Ana Bio | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Alameda, CA | |
| Sudo Biosciences | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Carmel, IN |
Shinichiro Fuse Ph.D Lead Partner on Deals (6)
Shinichiro Fuse Ph.D has been the lead partner on 6 deals. Their latest deal was with Ouro Medicines, a biotechnology company. The deal was made for on 10-Jan-2025.
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| Ouro Medicines | 10-Jan-2025 | Early Stage VC (Series A) | Completed | Biotechnology | San Francisco, CA | |
| Santa Ana Bio | 13-Jun-2024 | Completed | Drug Discovery | Alameda, CA | ||
| Sudo Biosciences | 01-Jan-2024 | Completed | Drug Discovery | Carmel, IN | ||
| Santa Ana Bio | 16-Feb-2023 | Completed | Drug Discovery | Alameda, CA | ||
| Orna Therapeutics | 24-Feb-2021 | Early Stage VC (Series A) | Completed | Drug Delivery | Cambridge, MA | |
| Triplet Therapeutics | 01-Nov-2019 | Early Stage VC (Series A) | Completed | Drug Discovery | Cambridge, MA |
Shinichiro Fuse Ph.D Network (102)
Board Members (54)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Kazunori Maruyama Ph.D | Coda Biotherapeutics | Astellas Venture Management | South San Francisco, CA | |
| Thomas Ebeling | Orna Therapeutics | MPM BioImpact | Cambridge, MA | |
| Santa Ana Bio | Santa Ana Bio | Alameda, CA | ||
| Orna Therapeutics | BioImpact Capital | Cambridge, MA | ||
| Triplet Therapeutics | Self | Cambridge, MA |
Portfolio Executives (35)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| Kevin Baker Ph.D | Ouro Medicines | Chief Development Officer | 10-Jan-2025 | San Francisco, CA |
| Jaideep Dudani Ph.D | Ouro Medicines | Chief Executive Officer & Board Member | 10-Jan-2025 | San Francisco, CA |
| Ouro Medicines | Chief Administrative Officer | 10-Jan-2025 | San Francisco, CA | |
| Ouro Medicines | Chief Medical Officer | 10-Jan-2025 | San Francisco, CA | |
| Santa Ana Bio | Co-Founder, Chief Executive Officer & Board Member | 13-Jun-2024 | Alameda, CA |
Fund Team Members (13)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Carolyn Ng Ph.D | TPG | TPG Life Sciences Innovations Fund | Fort Worth, TX |
| Gary Patou MD | MPM BioImpact | MPM BioVentures 2018 | Boston, MA |
| TPG | Fort Worth, TX | ||
| TPG | Fort Worth, TX | ||
| MPM BioImpact | Boston, MA |
Shinichiro Fuse Ph.D Affiliated Funds (3)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| TPG Life Sciences Innovations Fund | TPG | Venture - General | Closed | 2023 | ||||
| MPM BioVentures 2018 | MPM BioImpact | Venture Capital - Early Stage | Closed | 2019 | ||||
| The Rise Fund III | TPG | Growth/Expansion | Closed | 2022 |
Shinichiro Fuse Ph.D FAQs
-
Who is Shinichiro Fuse Ph.D?
Dr. Shinichiro Fuse serves as Partner & Managing Director at TPG.
-
How much does Shinichiro Fuse Ph.D typically invest?
Shinichiro Fuse Ph.D's median deal size is .
-
What is Shinichiro Fuse Ph.D’s main position?
Shinichiro Fuse Ph.D’s primary position is Partner & Managing Director.
-
What are the contact details for Shinichiro Fuse Ph.D?
Shinichiro Fuse Ph.D’s email address is sf and his phone number is +1 (212) .
-
How many active board seats does Shinichiro Fuse Ph.D hold?
Shinichiro Fuse Ph.D holds 3 board seats including Ouro Medicines, Santa Ana Bio, and Sudo Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
